Montelukast AG Achieves Rapid Market Penetration, Enjoys Stronger Start than Candesartan AG

February 7, 2017
By Reiji Anasako This is what an authorized generic can do. Reporting its earnings for April-December 2016, Kyorin Holdings said on February 3 that its montelukast authorized generic (AG; original product: Kipres/Singulair), which was launched in September, racked up sales...read more